Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Preferred Shares (2016 - 2023)

Ovid Therapeutics filings provide 7 years of Preferred Shares readings, the most recent being $1.0 for Q3 2023.

  • Quarterly Preferred Shares changed 0.0% to $1.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $1.0 through Sep 2023, changed 0.0% year-over-year, with the annual reading at $1.0 for FY2022, 0.0% changed from the prior year.
  • Preferred Shares hit $1.0 in Q3 2023 for Ovid Therapeutics, roughly flat from $1.0 in the prior quarter.
  • Across five years, Preferred Shares topped out at $8.0 in Q4 2019 and bottomed at $1.0 in Q1 2021.
  • Average Preferred Shares over 5 years is $2.74, with a median of $1.0 recorded in 2021.
  • The largest annual shift saw Preferred Shares soared 166.67% in 2020 before it plummeted 87.5% in 2021.
  • Ovid Therapeutics' Preferred Shares stood at $8.0 in 2019, then crashed by 62.5% to $3.0 in 2020, then tumbled by 66.67% to $1.0 in 2021, then changed by 0.0% to $1.0 in 2022, then changed by 0.0% to $1.0 in 2023.
  • Per Business Quant, the three most recent readings for OVID's Preferred Shares are $1.0 (Q3 2023), $1.0 (Q2 2023), and $1.0 (Q1 2023).